Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Akorn

This page shows the latest Akorn news and features for those working in and with pharma, biotech and healthcare.

Data integrity scuppers Fresenius deal with Akorn

Data integrity scuppers Fresenius deal with Akorn

Data integrity scuppers Fresenius deal with Akorn. However Fresenius could be liable to pay $129m in termination fees. ... Akorn can claim a termination fee, which in the original merger agreement was valued at $129m.

Latest news

  • Fresenius says Akorn investigation could affect takeover Fresenius says Akorn investigation could affect takeover

    Fresenius says Akorn investigation could affect takeover. External ‘experts’are investigating alleged breaches of data integrity requirements. ... Sales for Akorn’s small consumer health business stayed fairly constant at a little under $50m in the

  • Fresenius Kabi buys Akorn and Merck's biosimilar businesses Fresenius Kabi buys Akorn and Merck's biosimilar businesses

    Fresenius Kabi buys Akorn and Merck's biosimilar businesses. German-based firm predicts savings after it unites the two biopharma companies. ... Rumours of a deal have been circulating for several weeks, and Akorn confirmed it was in negotiations with

  • Archive listing

    Fresenius says Akorn investigation could affect takeover.

  • Lundbeck signs shark antibody deal with Ossianix

    Lundbeck signs shark antibody deal with Ossianix. Danish firm also plans to sell three injectable products to Indian company Akorn Inc. ... Akorn is gaining US entitlement to the products, and Lundbeck is not retaining any royalty rights.

  • Survival strategy

    A recent example of Big Pharma's entry into the generic marketplace was the purchase by Pfizer in December of 22 abbreviated new drug applications for $56m from the Akorn-Strides ... 80. Akorn-Strides/Pfizer. Acquisition of 22 ANDAs in US. Registration.

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch - May 2017 Deal Watch - May 2017

    In addition at the end of 2016 Akorn had net debt of around $600m and operating cash flow of $168m. ... 6, 100. Akorn (US). Fresenius (DE). Company acquisition. Manufacturing facilities and generic ophthalmic products with $1.1bn sales.

  • Pharma deals during September 2014 Pharma deals during September 2014

    The contract manufacturing sector is in a state of flux with the acquisition of Patheon last year by DSM and Akorn's acquisition of the ophthalmic manufacturer Excelvision in July this

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    45. ECR Pharmaceuticals / Valeant. Company acquisition. Akorn subsidiary with branded generics business.

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    VersaPharm / Akorn. Company acquisition. US generic company selling dermatology products with $100m sales.

  • Pharma deals during May 2014 Pharma deals during May 2014

    Merck sold its US ophthalmic business in 2013 for 1.5 x sales to Akorn. ... Akorn is better known for its ophthalmic business where it acquired three products from Merck &Co in November 2013 for $53m.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Quick links

Infographics

Multimedia